Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings

References

• Fenaux P, Ades L. How we treat lower-risk myelodysplastic syndromes. Blood. 2013;121:4280–4286.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Patel SS, Sekeres MA, Nazha A. Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure. Leuk Lymphoma. 2017;1–8.
   Google Scholar
• McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009;15:3927–3937.
   PubMed Web of Science ®Google Scholar
• Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One. 2010;5:e9001.
   PubMed Web of Science ®Google Scholar
• Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23:1019–1028. Epub 2009/02/06.
   PubMed Web of Science ®Google Scholar
• Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-2ʹ-deoxycytidine in human cancer cell lines. Blood. 2009;113:659–667. Epub 2008/10/22.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDSSSG. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al., Cancer, Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the cancer and leukemia group B. J Clin Oncol. 2006;24:3895–3903.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Al Ali NH, Padron E, et al. Lenalidomide treatment for lower risk nondeletion 5q myelodysplastic syndromes patients yields higher response rates when used before azacitidine. Clin Lymphoma Myeloma Leuk. 2015;15:705–710.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. Myelodysplastic syndromes: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:831–841.
   PubMed Web of Science ®Google Scholar
• Roberts DA, Steensma DP. Outlook and management of patients with myelodysplastic syndromes failed by hypomethylating agents. Curr Hematol Malig Rep. 2015;10:318–328.
   PubMed Web of Science ®Google Scholar
• Komrokji RS. Treatment of higher-risk myelodysplastic syndromes after failure of hypomethylating agents. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S56–9.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Kharfan-Dabaja MA, Komrokji RS. Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol. 2014;21:123–130.
   PubMed Web of Science ®Google Scholar
• Ball B, Zeidan A, Gore SD, et al. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leuk Lymphoma. 2016;5:1–15.
   Web of Science ®Google Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29:3322–3327.
   PubMed Web of Science ®Google Scholar
• Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014;38:1381–1391.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007;25:3503–3510.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351–1361.
   PubMed Web of Science ®Google Scholar
• Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011;96:441–449. Epub 2010/12/08.
   PubMed Web of Science ®Google Scholar
• Otrock ZK, Tiu RV, Maciejewski JP, et al. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol. 2013;6:59–68.
   PubMed Web of Science ®Google Scholar
• List AF, Bennett JM, Sekeres MA, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 2014;28:1033–1040.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. J Clin Oncol. 2011;29:303–309.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28:5166–5173.
   PubMed Web of Science ®Google Scholar
• Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34:2988–2996.
   PubMed Web of Science ®Google Scholar
• Toma A, Kosmider O, Chevret S, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30:897–905.
   PubMed Web of Science ®Google Scholar
• Platzbecker U. Biomarkers of ineffective erythropoiesis predict response to luspatercept in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): final results from the phase 2 PACE-MDS study. ASH Conference 2015. 2015.
   Google Scholar
• Raza A, Galili N, Smith SE, et al. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 2012;118:2138–2147.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Al-Kali A, Begna KH, et al. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J. 2016;6:e405.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Al-Ali HK, Gattermann N, et al. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. Leukemia. 2014;28:696–698.
   PubMed Web of Science ®Google Scholar
• Cashen A, Juckett M, Jumonville A, et al. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Ann Hematol. 2012;91:33–38.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Gore SD, Kambhampati S, et al. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016;30:889–896.
   PubMed Web of Science ®Google Scholar
• Raza A. Oral Rigosertib (ON 01910.Na) treatment produces an encouraging rate of transfusion independence in lower risk myelodysplastic syndromes (MDS) patients; a genomic methylation profile is associated with responses. ASH Conference 2013. 2013.
   Google Scholar
• Garcia-Manero G, Khoury HJ, Jabbour E, et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015;21:985–994.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943–2964.
   PubMed Web of Science ®Google Scholar
• NCCN. 2016. Myelodysplastic syndrome. [updated 2016 Nov 10; cited 2016 Dec 31]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf.
   Google Scholar
• Park S, Fenaux P, Greenberg P, et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol. 2016;174:730–747.
   PubMed Web of Science ®Google Scholar
• Almeida A, Fenaux P, List AF, et al. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leuk Res. 2017;52:50–57.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27:1283–1290.
   PubMed Web of Science ®Google Scholar
• Park S, Hamel JF, Toma A, et al. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J Clin Oncol. 2017;35:1591–1597.
   PubMed Web of Science ®Google Scholar
• Scott BL, Ramakrishnan A, Fosdal M, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010;149:706–710.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116:3830–3834.
   PubMed Web of Science ®Google Scholar
• Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585.
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Porta MG, Malcovati L, et al. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol. 2013;88:581–588.
   PubMed Web of Science ®Google Scholar
• Robin M, Porcher R, Zinke-Cerwenka W, et al. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the chronic malignancy working party of the EBMT. Bone Marrow Transplant. 2016;52:1081.
   PubMed Web of Science ®Google Scholar
• Basiorka AA, McGraw KL, De Ceuninck L, et al. Lenalidomide stabilizes the erythropoietin receptor by inhibiting the E3 ubiquitin ligase RNF41. Cancer Res. 2016;76:3531–3540.
   PubMed Web of Science ®Google Scholar
• Prebet T, Toma A, Cluzeau T, et al. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget. 2017;8(23):37866–37874.
   Web of Science ®Google Scholar
• Giagounidis A. Luspatercept treatment leads to long term increases in hemoglobin and reductions in transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): preliminary results from the phase 2 PACE-MDS extension study. ASH Conference 2015. 2015.
   Google Scholar
• Malcovati L, Cazzola M. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. Br J Haematol. 2016;174:847–858.
   PubMed Web of Science ®Google Scholar
• Galili N, Tamayo P, Botvinnik OB, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012;5:20.
   PubMed Web of Science ®Google Scholar
• Raza A, Galili N, Mulford D, et al. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012;5:18.
   PubMed Web of Science ®Google Scholar
• Zhao X, Tian X, Kajigaya S, et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016;175:427–439.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Raza A, Lancet JE, et al. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol. 2013;162:517–524.
   PubMed Web of Science ®Google Scholar
• Ball B Evaluation of salvage induction chemotherapy regimens in higher risk myelodysplastic syndrome and acute myeloid leukemia after hypomethylating agent treatment failure. ASH Conference; 2016.
   Google Scholar
• Harel S, Cherait A, Berthon C, et al. Outcome of patients with high risk myelodysplastic syndrome (MDS) and advanced chronic myelomonocytic leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res. 2015;39:501–504.
   PubMed Web of Science ®Google Scholar
• Duong VH, Bhatnagar B, Zandberg DP, et al. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leuk Lymphoma. 2015;56:1718–1722.
   PubMed Web of Science ®Google Scholar
• Issa JP, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015;16:1099–1110.
   PubMed Web of Science ®Google Scholar
• Prebet T, Charbonnier A, Gelsi-Boyer V, et al. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leuk Lymphoma. 2013;54:1538–1540.
   PubMed Web of Science ®Google Scholar
• Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009;113:3947–3952.
   PubMed Web of Science ®Google Scholar
• Cherian MA, Tibes R, Gao F, et al. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. Leuk Lymphoma. 2016;57:2535–2540.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Smith BD, Carraway HE, et al. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Br J Haematol. 2016;176(2):241–247.
   Web of Science ®Google Scholar
• Stein E. Enasidenib (AG-221), a potent oral inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzyme, induces hematologic responses in patients with myelodysplastic syndromes (MDS). ASH Conference 2016. 2016.
   Google Scholar
• DiNardo CD. A phase I study of IDH305 in patients with advanced malignancies including relapsed/refractory AML and MDS that harbor IDH1R132 mutations. ASH Conference 2016. 2016.
   Google Scholar
• Vey N, Prebet T, Thalamas C, et al. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leuk Lymphoma. 2016;58(8):1880–1886.
   Web of Science ®Google Scholar
• Faderl S, Garcia-Manero G, Estrov Z, et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010;28:2755–2760.
   PubMed Web of Science ®Google Scholar
• Lim SH, McMahan J, Zhang J, et al. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. Leuk Lymphoma. 2010;51:2258–2261.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Faderl S, Sasaki K, et al. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2016;123(4):629–637.
   Web of Science ®Google Scholar
• Kantarjian H, Garcia-Manero G, O’Brien S, et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010;28:285–291.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents. J Clin Oncol. 2010. DOI: 10.1200/jco.2009.27.15s.7021
   Google Scholar
• Garcia-Manero G A randomized phase II study of sapacitabine In MDS refractory to hypomethylating agents ASH Conference 2013. 2013.
   Google Scholar
• Garcia-Manero G, Fenaux P, Al-Kali A, et al., investigators Os. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496–508.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Greenberg P, Raza A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol. 2015;33:57–66.
   PubMed Web of Science ®Google Scholar
• Duong VH, Jaglal MV, Zhang L, et al. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leuk Res. 2013;37:300–304.
   PubMed Web of Science ®Google Scholar
• Thepot S, Boehrer S, Seegers V, et al. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res. 2014;38:1430–1434.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Padron E, Yu D, et al. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. Am J Hematol. 2014;89:809–812.
   PubMed Web of Science ®Google Scholar
• Zeidan AM. A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure. J Clin Oncol. 2017;35.
   Google Scholar
• Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013;31:2662–2670.
   PubMed Web of Science ®Google Scholar
• Damaj G. Impact of Azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol. 2012;30(36):4533–4540.
   Web of Science ®Google Scholar
• Sebert M. Equivalent outcome between reduced intensity versus conventional myeloablative conditioning hematopoietic stem cell transplantation for patients older than 35 years with acute myeloid leukemia. ASH Conference 2012. 2012.
   Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
   PubMed Web of Science ®Google Scholar
• Nazha A, Komrokji RS, Garcia-Manero G, et al. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016;101:e224–7.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49:690–695.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymphoma Myeloma Leuk. 2012;12:341–344.
   PubMed Web of Science ®Google Scholar
• Stahl M, Gore SD, Vey N, et al. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2016;25:307–317.
   PubMed Web of Science ®Google Scholar
• Prebet T, Braun T, Beyne-Rauzy O, et al. Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leuk Res. 2014;38:29–33.
   PubMed Web of Science ®Google Scholar
• Prebet T, Delaunay J, Wattel E, et al. Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add-on study from the groupe francophone des myelodysplasies. Br J Haematol. 2016. DOI: 10.1111/bjh.14427
   Google Scholar
• Rudrapatna VK, Morley K, Boucher KM, et al. Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leuk Res. 2015;39:835–839.
   PubMed Web of Science ®Google Scholar
• Roberts DA, Wadleigh M, McDonnell AM, et al. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015;39:204–210.
   PubMed Web of Science ®Google Scholar
• Boehrer S, Ades L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood. 2008;111:2170–2180.
   PubMed Web of Science ®Google Scholar
• Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–1288.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G. A phase II study evaluating the combination of nivolumab (Nivo) or ipilimumab (Ipi) with azacitidine in Pts with previously treated or untreated myelodysplastic syndromes (MDS). ASH Conference 2016. 2016.
   Google Scholar
• Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009;114:3448–3458.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147–1152.
   PubMed Web of Science ®Google Scholar
• Prebet T. Abstract: prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US leukemia intergroup trial E1905. J Clin Oncol. 2014.
   PubMed Web of Science ®Google Scholar
• Jabbour E A randomized phase ii study of low-dose decitabine versus azacitidine in patients with low- or intermediate-1-risk myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium. ASH Conference 2016. 2016.
   Google Scholar
• Sekeres MA Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with Vorinostat Vs. Azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup Study SWOG S1117. ASH Conference 2015. 2015.
   Google Scholar
• Prebet T. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. J Clin Oncol. 2014;32:1242–1248.
   PubMed Web of Science ®Google Scholar